KR102594251B1 - 화합물, 상기 화합물을 얻기 위한 공정, 약제학적 조성물, 상기 화합물의 용도 및 정신 장애 및/또한 수면 장애를 치료하기 위한 방법 - Google Patents
화합물, 상기 화합물을 얻기 위한 공정, 약제학적 조성물, 상기 화합물의 용도 및 정신 장애 및/또한 수면 장애를 치료하기 위한 방법 Download PDFInfo
- Publication number
- KR102594251B1 KR102594251B1 KR1020197011842A KR20197011842A KR102594251B1 KR 102594251 B1 KR102594251 B1 KR 102594251B1 KR 1020197011842 A KR1020197011842 A KR 1020197011842A KR 20197011842 A KR20197011842 A KR 20197011842A KR 102594251 B1 KR102594251 B1 KR 102594251B1
- Authority
- KR
- South Korea
- Prior art keywords
- formula
- ethyl
- compound
- benzimidazol
- methoxy
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 150000001875 compounds Chemical class 0.000 title claims abstract description 258
- 238000000034 method Methods 0.000 title claims abstract description 28
- 230000008569 process Effects 0.000 title claims abstract description 20
- 208000019116 sleep disease Diseases 0.000 title claims abstract description 17
- 208000020016 psychiatric disease Diseases 0.000 title claims abstract description 16
- 239000008194 pharmaceutical composition Substances 0.000 title claims abstract description 13
- -1 benzimidazole derivative compounds Chemical class 0.000 claims abstract description 37
- 238000011282 treatment Methods 0.000 claims abstract description 16
- 125000000217 alkyl group Chemical group 0.000 claims description 65
- 238000006243 chemical reaction Methods 0.000 claims description 37
- 125000004435 hydrogen atom Chemical group [H]* 0.000 claims description 36
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 claims description 31
- 229910052739 hydrogen Inorganic materials 0.000 claims description 29
- 239000001257 hydrogen Substances 0.000 claims description 29
- DLFVBJFMPXGRIB-UHFFFAOYSA-N Acetamide Chemical compound CC(N)=O DLFVBJFMPXGRIB-UHFFFAOYSA-N 0.000 claims description 28
- JRNVZBWKYDBUCA-UHFFFAOYSA-N N-chlorosuccinimide Chemical compound ClN1C(=O)CCC1=O JRNVZBWKYDBUCA-UHFFFAOYSA-N 0.000 claims description 26
- 239000003814 drug Substances 0.000 claims description 26
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims description 21
- 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 claims description 20
- UMGDCJDMYOKAJW-UHFFFAOYSA-N thiourea Chemical compound NC(N)=S UMGDCJDMYOKAJW-UHFFFAOYSA-N 0.000 claims description 20
- CWLNAJYDRSIKJS-UHFFFAOYSA-N triethoxymethoxyethane Chemical compound CCOC(OCC)(OCC)OCC CWLNAJYDRSIKJS-UHFFFAOYSA-N 0.000 claims description 20
- PCLIMKBDDGJMGD-UHFFFAOYSA-N N-bromosuccinimide Chemical compound BrN1C(=O)CCC1=O PCLIMKBDDGJMGD-UHFFFAOYSA-N 0.000 claims description 18
- GDTBXPJZTBHREO-UHFFFAOYSA-N bromine Substances BrBr GDTBXPJZTBHREO-UHFFFAOYSA-N 0.000 claims description 18
- 150000001244 carboxylic acid anhydrides Chemical class 0.000 claims description 18
- 125000002962 imidazol-1-yl group Chemical group [*]N1C([H])=NC([H])=C1[H] 0.000 claims description 18
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 claims description 18
- 229910052801 chlorine Inorganic materials 0.000 claims description 17
- 125000000753 cycloalkyl group Chemical group 0.000 claims description 17
- LQZMLBORDGWNPD-UHFFFAOYSA-N N-iodosuccinimide Chemical compound IN1C(=O)CCC1=O LQZMLBORDGWNPD-UHFFFAOYSA-N 0.000 claims description 16
- 229910052794 bromium Inorganic materials 0.000 claims description 15
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims description 14
- AHJWSRRHTXRLAQ-UHFFFAOYSA-N tetramethoxymethane Chemical compound COC(OC)(OC)OC AHJWSRRHTXRLAQ-UHFFFAOYSA-N 0.000 claims description 14
- 125000003342 alkenyl group Chemical group 0.000 claims description 13
- 125000000304 alkynyl group Chemical group 0.000 claims description 13
- ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical compound [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 claims description 12
- 239000000460 chlorine Substances 0.000 claims description 12
- 125000001188 haloalkyl group Chemical group 0.000 claims description 12
- 229910052736 halogen Inorganic materials 0.000 claims description 12
- 150000002367 halogens Chemical class 0.000 claims description 12
- MRWHUOOPUIAFSB-UHFFFAOYSA-N N-[2-(2-ethoxy-6-methoxybenzimidazol-1-yl)ethyl]acetamide Chemical compound C(C)(=O)NCCN1C(=NC2=C1C=C(C=C2)OC)OCC MRWHUOOPUIAFSB-UHFFFAOYSA-N 0.000 claims description 11
- 239000002168 alkylating agent Substances 0.000 claims description 11
- 229940100198 alkylating agent Drugs 0.000 claims description 11
- ZCYVEMRRCGMTRW-UHFFFAOYSA-N 7553-56-2 Chemical compound [I] ZCYVEMRRCGMTRW-UHFFFAOYSA-N 0.000 claims description 10
- WKBOTKDWSSQWDR-UHFFFAOYSA-N Bromine atom Chemical compound [Br] WKBOTKDWSSQWDR-UHFFFAOYSA-N 0.000 claims description 10
- XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Natural products NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 claims description 10
- 239000012351 deprotecting agent Substances 0.000 claims description 10
- 229910052740 iodine Inorganic materials 0.000 claims description 10
- 239000011630 iodine Substances 0.000 claims description 10
- 239000003638 chemical reducing agent Substances 0.000 claims description 8
- 239000003795 chemical substances by application Substances 0.000 claims description 7
- 125000005843 halogen group Chemical group 0.000 claims description 7
- BIZPRFMEEMOSNC-UHFFFAOYSA-N N-[2-(2-ethoxy-6-methoxybenzimidazol-1-yl)ethyl]cyclopropanecarboxamide Chemical compound C1(CC1)C(=O)NCCN1C(=NC2=C1C=C(C=C2)OC)OCC BIZPRFMEEMOSNC-UHFFFAOYSA-N 0.000 claims description 6
- HJOUELOCKKMZBA-UHFFFAOYSA-N N-[3-(2-ethoxy-6-methoxybenzimidazol-1-yl)propyl]acetamide Chemical compound C(C)(=O)NCCCN1C(=NC2=C1C=C(C=C2)OC)OCC HJOUELOCKKMZBA-UHFFFAOYSA-N 0.000 claims description 6
- 230000002140 halogenating effect Effects 0.000 claims description 6
- 125000004430 oxygen atom Chemical group O* 0.000 claims description 6
- OSKMTHQTYBZVLY-UHFFFAOYSA-N N-[2-(2,6-dimethoxybenzimidazol-1-yl)ethyl]acetamide Chemical compound C(C)(=O)NCCN1C(=NC2=C1C=C(C=C2)OC)OC OSKMTHQTYBZVLY-UHFFFAOYSA-N 0.000 claims description 5
- IGBXTAHNBAVPGY-UHFFFAOYSA-N N-[3-(2,6-dimethoxybenzimidazol-1-yl)propyl]acetamide Chemical compound C(C)(=O)NCCCN1C(=NC2=C1C=C(C=C2)OC)OC IGBXTAHNBAVPGY-UHFFFAOYSA-N 0.000 claims description 5
- 125000001309 chloro group Chemical group Cl* 0.000 claims description 5
- 238000004519 manufacturing process Methods 0.000 claims description 4
- ZQKKQGMSTLKATQ-UHFFFAOYSA-N 2-bromo-N-[2-(2-ethoxy-6-methoxybenzimidazol-1-yl)ethyl]acetamide Chemical compound CCOC1=NC2=CC=C(OC)C=C2N1CCNC(=O)CBr ZQKKQGMSTLKATQ-UHFFFAOYSA-N 0.000 claims description 3
- REFADFWJUIEDOA-UHFFFAOYSA-N N-[1-(2-ethoxy-6-methoxybenzimidazol-1-yl)propan-2-yl]acetamide Chemical compound C(C)(=O)NC(CN1C(=NC2=C1C=C(C=C2)OC)OCC)C REFADFWJUIEDOA-UHFFFAOYSA-N 0.000 claims description 3
- OTYNCFBIMOPRBT-UHFFFAOYSA-N N-[2-(2-ethoxy-6-methoxybenzimidazol-1-yl)ethyl]butanamide Chemical compound C(CCC)(=O)NCCN1C(=NC2=C1C=C(C=C2)OC)OCC OTYNCFBIMOPRBT-UHFFFAOYSA-N 0.000 claims description 3
- SWMZGIRIHACCTN-UHFFFAOYSA-N N-[2-(6-methoxy-2-methylsulfanylbenzimidazol-1-yl)ethyl]acetamide Chemical compound C(C)(=O)NCCN1C(=NC2=C1C=C(C=C2)OC)SC SWMZGIRIHACCTN-UHFFFAOYSA-N 0.000 claims description 3
- ISXMRHJAUNQJBR-UHFFFAOYSA-N N-[2-(2,6-dimethoxybenzimidazol-1-yl)ethyl]propanamide Chemical compound COC1=NC2=C(N1CCNC(CC)=O)C=C(C=C2)OC ISXMRHJAUNQJBR-UHFFFAOYSA-N 0.000 claims description 2
- QIOYUWITBFJOES-UHFFFAOYSA-N N-[2-(2-ethoxy-6-methoxybenzimidazol-1-yl)ethyl]cyclobutanecarboxamide Chemical compound C1(CCC1)C(=O)NCCN1C(=NC2=C1C=C(C=C2)OC)OCC QIOYUWITBFJOES-UHFFFAOYSA-N 0.000 claims description 2
- QRYQHXRSKHELJJ-UHFFFAOYSA-N N-[2-(2-ethoxy-6-methoxybenzimidazol-1-yl)ethyl]cyclohexanecarboxamide Chemical compound C1(CCCCC1)C(=O)NCCN1C(=NC2=C1C=C(C=C2)OC)OCC QRYQHXRSKHELJJ-UHFFFAOYSA-N 0.000 claims description 2
- DURORZYHZGDNML-UHFFFAOYSA-N N-[2-(2-ethoxy-6-methoxybenzimidazol-1-yl)ethyl]cyclopentanecarboxamide Chemical compound C1(CCCC1)C(=O)NCCN1C(=NC2=C1C=C(C=C2)OC)OCC DURORZYHZGDNML-UHFFFAOYSA-N 0.000 claims description 2
- VQPBJJRBTBYILE-UHFFFAOYSA-N N-[2-(2-ethoxy-6-methoxybenzimidazol-1-yl)ethyl]propanamide Chemical compound C(C)OC1=NC2=C(N1CCNC(CC)=O)C=C(C=C2)OC VQPBJJRBTBYILE-UHFFFAOYSA-N 0.000 claims description 2
- ASKLTMFCZWTEIQ-UHFFFAOYSA-N N-[2-(5-bromo-2-ethoxy-6-methoxybenzimidazol-1-yl)ethyl]acetamide Chemical compound C(C)(=O)NCCN1C(=NC2=C1C=C(C(=C2)Br)OC)OCC ASKLTMFCZWTEIQ-UHFFFAOYSA-N 0.000 claims description 2
- BVSLRGAPRGQWNC-UHFFFAOYSA-N N-[2-(5-chloro-2,6-dimethoxybenzimidazol-1-yl)ethyl]acetamide Chemical compound C(C)(=O)NCCN1C(=NC2=C1C=C(C(=C2)Cl)OC)OC BVSLRGAPRGQWNC-UHFFFAOYSA-N 0.000 claims description 2
- LRRDNGSYVNSAEO-UHFFFAOYSA-N N-[2-(5-chloro-2-ethoxy-6-methoxybenzimidazol-1-yl)ethyl]acetamide Chemical compound C(C)(=O)NCCN1C(=NC2=C1C=C(C(=C2)Cl)OC)OCC LRRDNGSYVNSAEO-UHFFFAOYSA-N 0.000 claims description 2
- ZJBOWGCBTCJJNG-UHFFFAOYSA-N N-[2-(5-chloro-2-ethoxy-6-methoxybenzimidazol-1-yl)ethyl]cyclopropanecarboxamide Chemical compound C1(CC1)C(=O)NCCN1C(=NC2=C1C=C(C(=C2)Cl)OC)OCC ZJBOWGCBTCJJNG-UHFFFAOYSA-N 0.000 claims description 2
- ZEHKUOUEYCAMRA-UHFFFAOYSA-N N-[2-(7-chloro-2-ethoxy-6-methoxybenzimidazol-1-yl)ethyl]acetamide Chemical compound C(C)(=O)NCCN1C(=NC2=C1C(=C(C=C2)OC)Cl)OCC ZEHKUOUEYCAMRA-UHFFFAOYSA-N 0.000 claims description 2
- SGRBZRWEJGNQTA-UHFFFAOYSA-N N-[3-(5-chloro-2,6-dimethoxybenzimidazol-1-yl)propyl]acetamide Chemical compound C(C)(=O)NCCCN1C(=NC2=C1C=C(C(=C2)Cl)OC)OC SGRBZRWEJGNQTA-UHFFFAOYSA-N 0.000 claims description 2
- IYSSQVBXXUIIGE-UHFFFAOYSA-N N-[3-(5-chloro-2-ethoxy-6-methoxybenzimidazol-1-yl)propyl]acetamide Chemical compound C(C)(=O)NCCCN1C(=NC2=C1C=C(C(=C2)Cl)OC)OCC IYSSQVBXXUIIGE-UHFFFAOYSA-N 0.000 claims description 2
- FYOPITGSWFKTOI-UHFFFAOYSA-N N-[2-(2,6-dimethoxybenzimidazol-1-yl)ethyl]butanamide Chemical compound COC1=NC2=C(N1CCNC(CCC)=O)C=C(C=C2)OC FYOPITGSWFKTOI-UHFFFAOYSA-N 0.000 claims 1
- 239000000203 mixture Substances 0.000 abstract description 34
- DRLFMBDRBRZALE-UHFFFAOYSA-N melatonin Chemical compound COC1=CC=C2NC=C(CCNC(C)=O)C2=C1 DRLFMBDRBRZALE-UHFFFAOYSA-N 0.000 abstract description 31
- YJPIGAIKUZMOQA-UHFFFAOYSA-N Melatonin Natural products COC1=CC=C2N(C(C)=O)C=C(CCN)C2=C1 YJPIGAIKUZMOQA-UHFFFAOYSA-N 0.000 abstract description 29
- 229960003987 melatonin Drugs 0.000 abstract description 29
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract description 9
- 108010074922 Cytochrome P-450 CYP1A2 Proteins 0.000 abstract description 8
- 102000004190 Enzymes Human genes 0.000 abstract description 7
- 108090000790 Enzymes Proteins 0.000 abstract description 7
- 208000035475 disorder Diseases 0.000 abstract description 6
- 208000019901 Anxiety disease Diseases 0.000 abstract description 4
- 230000036506 anxiety Effects 0.000 abstract description 4
- 230000000750 progressive effect Effects 0.000 abstract description 4
- 102000008144 Cytochrome P-450 CYP1A2 Human genes 0.000 abstract 1
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 135
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 90
- 239000000243 solution Substances 0.000 description 76
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 72
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 64
- 238000003756 stirring Methods 0.000 description 59
- CSNNHWWHGAXBCP-UHFFFAOYSA-L Magnesium sulfate Chemical compound [Mg+2].[O-][S+2]([O-])([O-])[O-] CSNNHWWHGAXBCP-UHFFFAOYSA-L 0.000 description 58
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 57
- 239000012429 reaction media Substances 0.000 description 51
- 239000007787 solid Substances 0.000 description 38
- YJYPHIXNFHFHND-UHFFFAOYSA-N agomelatine Chemical compound C1=CC=C(CCNC(C)=O)C2=CC(OC)=CC=C21 YJYPHIXNFHFHND-UHFFFAOYSA-N 0.000 description 35
- 229960002629 agomelatine Drugs 0.000 description 34
- CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 description 32
- HEDRZPFGACZZDS-MICDWDOJSA-N Trichloro(2H)methane Chemical compound [2H]C(Cl)(Cl)Cl HEDRZPFGACZZDS-MICDWDOJSA-N 0.000 description 32
- 239000012265 solid product Substances 0.000 description 31
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 30
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 30
- 239000012074 organic phase Substances 0.000 description 28
- 238000001990 intravenous administration Methods 0.000 description 25
- 229910052943 magnesium sulfate Inorganic materials 0.000 description 24
- 235000019341 magnesium sulphate Nutrition 0.000 description 24
- 229940079593 drug Drugs 0.000 description 22
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 21
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical class [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 20
- 230000036470 plasma concentration Effects 0.000 description 20
- 238000003820 Medium-pressure liquid chromatography Methods 0.000 description 19
- 125000003785 benzimidazolyl group Chemical class N1=C(NC2=C1C=CC=C2)* 0.000 description 19
- 102000001419 Melatonin receptor Human genes 0.000 description 17
- 108050009605 Melatonin receptor Proteins 0.000 description 17
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 16
- 229910000029 sodium carbonate Inorganic materials 0.000 description 16
- WFDIJRYMOXRFFG-UHFFFAOYSA-N Acetic anhydride Chemical compound CC(=O)OC(C)=O WFDIJRYMOXRFFG-UHFFFAOYSA-N 0.000 description 15
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 15
- 125000004169 (C1-C6) alkyl group Chemical group 0.000 description 14
- 239000000543 intermediate Substances 0.000 description 14
- 229910052760 oxygen Inorganic materials 0.000 description 13
- 239000000047 product Substances 0.000 description 13
- 102100029698 Metallothionein-1A Human genes 0.000 description 12
- 229910052717 sulfur Inorganic materials 0.000 description 12
- 125000005913 (C3-C6) cycloalkyl group Chemical group 0.000 description 11
- 102100024930 Melatonin receptor type 1A Human genes 0.000 description 11
- 101710098568 Melatonin receptor type 1A Proteins 0.000 description 11
- HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 description 11
- 230000015572 biosynthetic process Effects 0.000 description 11
- 239000001301 oxygen Substances 0.000 description 11
- 102000005962 receptors Human genes 0.000 description 11
- 108020003175 receptors Proteins 0.000 description 11
- 238000012360 testing method Methods 0.000 description 11
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 11
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 10
- 102100024970 Melatonin receptor type 1B Human genes 0.000 description 10
- 101710098567 Melatonin receptor type 1B Proteins 0.000 description 10
- 239000000556 agonist Substances 0.000 description 10
- VZTDIZULWFCMLS-UHFFFAOYSA-N ammonium formate Chemical compound [NH4+].[O-]C=O VZTDIZULWFCMLS-UHFFFAOYSA-N 0.000 description 10
- 239000000706 filtrate Substances 0.000 description 10
- 230000005484 gravity Effects 0.000 description 10
- 239000003446 ligand Substances 0.000 description 10
- 238000010992 reflux Methods 0.000 description 10
- 125000004434 sulfur atom Chemical group 0.000 description 10
- 125000006273 (C1-C3) alkyl group Chemical group 0.000 description 9
- 125000000171 (C1-C6) haloalkyl group Chemical group 0.000 description 9
- 125000000882 C2-C6 alkenyl group Chemical group 0.000 description 9
- 125000003601 C2-C6 alkynyl group Chemical group 0.000 description 9
- 101150051438 CYP gene Proteins 0.000 description 9
- 241000699670 Mus sp. Species 0.000 description 9
- 238000003760 magnetic stirring Methods 0.000 description 9
- 125000001424 substituent group Chemical group 0.000 description 9
- MYMOFIZGZYHOMD-UHFFFAOYSA-N Dioxygen Chemical compound O=O MYMOFIZGZYHOMD-UHFFFAOYSA-N 0.000 description 8
- 241001465754 Metazoa Species 0.000 description 8
- 230000000694 effects Effects 0.000 description 8
- 238000013213 extrapolation Methods 0.000 description 8
- 230000005764 inhibitory process Effects 0.000 description 8
- 238000003786 synthesis reaction Methods 0.000 description 8
- 239000011701 zinc Substances 0.000 description 8
- 229910052725 zinc Inorganic materials 0.000 description 8
- BVKZGUZCCUSVTD-UHFFFAOYSA-M Bicarbonate Chemical compound OC([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-M 0.000 description 7
- 102100026533 Cytochrome P450 1A2 Human genes 0.000 description 7
- YLXDSYKOBKBWJQ-LBPRGKRZSA-N N-[2-[(8S)-2,6,7,8-tetrahydro-1H-cyclopenta[e]benzofuran-8-yl]ethyl]propanamide Chemical compound C1=C2OCCC2=C2[C@H](CCNC(=O)CC)CCC2=C1 YLXDSYKOBKBWJQ-LBPRGKRZSA-N 0.000 description 7
- 239000008346 aqueous phase Substances 0.000 description 7
- 238000004587 chromatography analysis Methods 0.000 description 7
- 230000004060 metabolic process Effects 0.000 description 7
- NYEPVTVFVYEGIQ-UHFFFAOYSA-N n'-(5-methoxy-2-nitrophenyl)ethane-1,2-diamine Chemical compound COC1=CC=C([N+]([O-])=O)C(NCCN)=C1 NYEPVTVFVYEGIQ-UHFFFAOYSA-N 0.000 description 7
- 239000000126 substance Substances 0.000 description 7
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 6
- SIKJAQJRHWYJAI-UHFFFAOYSA-N Indole Chemical compound C1=CC=C2NC=CC2=C1 SIKJAQJRHWYJAI-UHFFFAOYSA-N 0.000 description 6
- 241000124008 Mammalia Species 0.000 description 6
- DTQVDTLACAAQTR-UHFFFAOYSA-N Trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-N 0.000 description 6
- 125000002619 bicyclic group Chemical group 0.000 description 6
- 238000004364 calculation method Methods 0.000 description 6
- 210000004027 cell Anatomy 0.000 description 6
- 238000001514 detection method Methods 0.000 description 6
- 210000003494 hepatocyte Anatomy 0.000 description 6
- 150000002430 hydrocarbons Chemical group 0.000 description 6
- 238000011534 incubation Methods 0.000 description 6
- 239000002207 metabolite Substances 0.000 description 6
- 229960001150 ramelteon Drugs 0.000 description 6
- 108010000543 Cytochrome P-450 CYP2C9 Proteins 0.000 description 5
- 102000018832 Cytochromes Human genes 0.000 description 5
- 108010052832 Cytochromes Proteins 0.000 description 5
- 241000282412 Homo Species 0.000 description 5
- 241000700159 Rattus Species 0.000 description 5
- 238000004458 analytical method Methods 0.000 description 5
- 238000011161 development Methods 0.000 description 5
- 238000010438 heat treatment Methods 0.000 description 5
- 238000004949 mass spectrometry Methods 0.000 description 5
- 230000007935 neutral effect Effects 0.000 description 5
- 239000000758 substrate Substances 0.000 description 5
- 230000001225 therapeutic effect Effects 0.000 description 5
- HYZJCKYKOHLVJF-UHFFFAOYSA-N 1H-benzimidazole Chemical compound C1=CC=C2NC=NC2=C1 HYZJCKYKOHLVJF-UHFFFAOYSA-N 0.000 description 4
- FERIUCNNQQJTOY-UHFFFAOYSA-N Butyric acid Chemical compound CCCC(O)=O FERIUCNNQQJTOY-UHFFFAOYSA-N 0.000 description 4
- PCBZRNYXXCIELG-WYFCWLEVSA-N COC1=CC=C(C[C@H](NC(=O)OC2CCCC3(C2)OOC2(O3)C3CC4CC(C3)CC2C4)C(=O)N[C@@H]2[C@@H](CO)O[C@H]([C@@H]2O)N2C=NC3=C2N=CN=C3N(C)C)C=C1 Chemical compound COC1=CC=C(C[C@H](NC(=O)OC2CCCC3(C2)OOC2(O3)C3CC4CC(C3)CC2C4)C(=O)N[C@@H]2[C@@H](CO)O[C@H]([C@@H]2O)N2C=NC3=C2N=CN=C3N(C)C)C=C1 PCBZRNYXXCIELG-WYFCWLEVSA-N 0.000 description 4
- 108010026925 Cytochrome P-450 CYP2C19 Proteins 0.000 description 4
- 102100029363 Cytochrome P450 2C19 Human genes 0.000 description 4
- 102100029358 Cytochrome P450 2C9 Human genes 0.000 description 4
- QUSNBJAOOMFDIB-UHFFFAOYSA-N Ethylamine Chemical compound CCN QUSNBJAOOMFDIB-UHFFFAOYSA-N 0.000 description 4
- UFWIBTONFRDIAS-UHFFFAOYSA-N Naphthalene Chemical compound C1=CC=CC2=CC=CC=C21 UFWIBTONFRDIAS-UHFFFAOYSA-N 0.000 description 4
- 208000013738 Sleep Initiation and Maintenance disease Diseases 0.000 description 4
- 239000002253 acid Substances 0.000 description 4
- 238000003556 assay Methods 0.000 description 4
- 229910052799 carbon Inorganic materials 0.000 description 4
- QTMDXZNDVAMKGV-UHFFFAOYSA-L copper(ii) bromide Chemical compound [Cu+2].[Br-].[Br-] QTMDXZNDVAMKGV-UHFFFAOYSA-L 0.000 description 4
- 238000009826 distribution Methods 0.000 description 4
- 206010022437 insomnia Diseases 0.000 description 4
- OOBUNZVYRUXQTM-UHFFFAOYSA-N n-[2-(2-amino-5-methoxyanilino)ethyl]acetamide Chemical compound COC1=CC=C(N)C(NCCNC(C)=O)=C1 OOBUNZVYRUXQTM-UHFFFAOYSA-N 0.000 description 4
- 230000035699 permeability Effects 0.000 description 4
- BWHMMNNQKKPAPP-UHFFFAOYSA-L potassium carbonate Chemical compound [K+].[K+].[O-]C([O-])=O BWHMMNNQKKPAPP-UHFFFAOYSA-L 0.000 description 4
- 230000036515 potency Effects 0.000 description 4
- 102000004169 proteins and genes Human genes 0.000 description 4
- 108090000623 proteins and genes Proteins 0.000 description 4
- 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 description 4
- FCEHBMOGCRZNNI-UHFFFAOYSA-N 1-benzothiophene Chemical compound C1=CC=C2SC=CC2=C1 FCEHBMOGCRZNNI-UHFFFAOYSA-N 0.000 description 3
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 3
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 3
- 102000001708 Protein Isoforms Human genes 0.000 description 3
- 108010029485 Protein Isoforms Proteins 0.000 description 3
- 239000004480 active ingredient Substances 0.000 description 3
- 229940058303 antinematodal benzimidazole derivative Drugs 0.000 description 3
- 125000003118 aryl group Chemical group 0.000 description 3
- 230000008901 benefit Effects 0.000 description 3
- 238000004891 communication Methods 0.000 description 3
- XBDQKXXYIPTUBI-UHFFFAOYSA-N dimethylselenoniopropionate Natural products CCC(O)=O XBDQKXXYIPTUBI-UHFFFAOYSA-N 0.000 description 3
- 201000010099 disease Diseases 0.000 description 3
- 231100000304 hepatotoxicity Toxicity 0.000 description 3
- 125000000623 heterocyclic group Chemical group 0.000 description 3
- 238000000589 high-performance liquid chromatography-mass spectrometry Methods 0.000 description 3
- 229930195733 hydrocarbon Natural products 0.000 description 3
- PZOUSPYUWWUPPK-UHFFFAOYSA-N indole Natural products CC1=CC=CC2=C1C=CN2 PZOUSPYUWWUPPK-UHFFFAOYSA-N 0.000 description 3
- RKJUIXBNRJVNHR-UHFFFAOYSA-N indolenine Natural products C1=CC=C2CC=NC2=C1 RKJUIXBNRJVNHR-UHFFFAOYSA-N 0.000 description 3
- 230000004048 modification Effects 0.000 description 3
- 238000012986 modification Methods 0.000 description 3
- 239000002547 new drug Substances 0.000 description 3
- 238000002360 preparation method Methods 0.000 description 3
- QLNJFJADRCOGBJ-UHFFFAOYSA-N propionamide Chemical compound CCC(N)=O QLNJFJADRCOGBJ-UHFFFAOYSA-N 0.000 description 3
- 229940080818 propionamide Drugs 0.000 description 3
- 230000009467 reduction Effects 0.000 description 3
- 239000011780 sodium chloride Substances 0.000 description 3
- 238000006467 substitution reaction Methods 0.000 description 3
- INAPMGSXUVUWAF-UOTPTPDRSA-N 1D-myo-inositol 1-phosphate Chemical compound O[C@H]1[C@H](O)[C@@H](O)[C@H](OP(O)(O)=O)[C@H](O)[C@@H]1O INAPMGSXUVUWAF-UOTPTPDRSA-N 0.000 description 2
- BJNBSKNWHBTCRL-UHFFFAOYSA-N 2-bromo-N-[2-(5-methoxy-2-nitroanilino)ethyl]acetamide Chemical compound COC1=CC(NCCNC(=O)CBr)=C(C=C1)[N+]([O-])=O BJNBSKNWHBTCRL-UHFFFAOYSA-N 0.000 description 2
- QTIDRIQSPAELJC-UHFFFAOYSA-N 2-chloro-4-methoxy-1-nitrobenzene Chemical compound COC1=CC=C([N+]([O-])=O)C(Cl)=C1 QTIDRIQSPAELJC-UHFFFAOYSA-N 0.000 description 2
- OLHOIERZAZMHGK-UHFFFAOYSA-N 7-ethoxy-4-(trifluoromethyl)chromen-2-one Chemical compound FC(F)(F)C1=CC(=O)OC2=CC(OCC)=CC=C21 OLHOIERZAZMHGK-UHFFFAOYSA-N 0.000 description 2
- IJQYTHQDUDCJEQ-UHFFFAOYSA-N 7-hydroxy-2-oxochromene-3-carbonitrile Chemical compound C1=C(C#N)C(=O)OC2=CC(O)=CC=C21 IJQYTHQDUDCJEQ-UHFFFAOYSA-N 0.000 description 2
- VMXQIFXZMOANFG-UHFFFAOYSA-N 7-hydroxy-3-(trifluoromethyl)chromen-2-one Chemical compound C1=C(C(F)(F)F)C(=O)OC2=CC(O)=CC=C21 VMXQIFXZMOANFG-UHFFFAOYSA-N 0.000 description 2
- XNZRYTITWLGTJS-UHFFFAOYSA-N 7-phenylmethoxyphenoxazin-3-one Chemical compound C1=C2OC3=CC(=O)C=CC3=NC2=CC=C1OCC1=CC=CC=C1 XNZRYTITWLGTJS-UHFFFAOYSA-N 0.000 description 2
- HBAQYPYDRFILMT-UHFFFAOYSA-N 8-[3-(1-cyclopropylpyrazol-4-yl)-1H-pyrazolo[4,3-d]pyrimidin-5-yl]-3-methyl-3,8-diazabicyclo[3.2.1]octan-2-one Chemical class C1(CC1)N1N=CC(=C1)C1=NNC2=C1N=C(N=C2)N1C2C(N(CC1CC2)C)=O HBAQYPYDRFILMT-UHFFFAOYSA-N 0.000 description 2
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 2
- 206010002091 Anaesthesia Diseases 0.000 description 2
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical group [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 2
- 229910021590 Copper(II) bromide Inorganic materials 0.000 description 2
- 108010020070 Cytochrome P-450 CYP2B6 Proteins 0.000 description 2
- 108010000561 Cytochrome P-450 CYP2C8 Proteins 0.000 description 2
- 108010001237 Cytochrome P-450 CYP2D6 Proteins 0.000 description 2
- 108010081668 Cytochrome P-450 CYP3A Proteins 0.000 description 2
- 102100038739 Cytochrome P450 2B6 Human genes 0.000 description 2
- 102100029359 Cytochrome P450 2C8 Human genes 0.000 description 2
- 102100021704 Cytochrome P450 2D6 Human genes 0.000 description 2
- 102100039205 Cytochrome P450 3A4 Human genes 0.000 description 2
- 206010013710 Drug interaction Diseases 0.000 description 2
- PXGOKWXKJXAPGV-UHFFFAOYSA-N Fluorine Chemical compound FF PXGOKWXKJXAPGV-UHFFFAOYSA-N 0.000 description 2
- XEEYBQQBJWHFJM-UHFFFAOYSA-N Iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 description 2
- YNVNEHXPBQFQJB-UHFFFAOYSA-N N-[1-(2-amino-5-methoxyanilino)propan-2-yl]acetamide Chemical compound C(C)(=O)NC(CNC1=C(C=CC(=C1)OC)N)C YNVNEHXPBQFQJB-UHFFFAOYSA-N 0.000 description 2
- GVGSWCWPSATSBJ-UHFFFAOYSA-N N-[2-(2-amino-5-methoxyanilino)ethyl]butanamide Chemical compound C(CCC)(=O)NCCNC1=C(C=CC(=C1)OC)N GVGSWCWPSATSBJ-UHFFFAOYSA-N 0.000 description 2
- WHQJZHJCXAFAPS-UHFFFAOYSA-N N-[2-(2-amino-5-methoxyanilino)ethyl]cyclohexanecarboxamide Chemical compound C1(CCCCC1)C(=O)NCCNC1=C(C=CC(=C1)OC)N WHQJZHJCXAFAPS-UHFFFAOYSA-N 0.000 description 2
- URBVGWHIUFENER-UHFFFAOYSA-N N-[2-(2-amino-5-methoxyanilino)ethyl]cyclopentanecarboxamide Chemical compound C1(CCCC1)C(=O)NCCNC1=C(C=CC(=C1)OC)N URBVGWHIUFENER-UHFFFAOYSA-N 0.000 description 2
- OBQOFTHBYGWDKA-UHFFFAOYSA-N N-[2-(2-amino-5-methoxyanilino)ethyl]cyclopropanecarboxamide Chemical compound C1(CC1)C(=O)NCCNC1=C(C=CC(=C1)OC)N OBQOFTHBYGWDKA-UHFFFAOYSA-N 0.000 description 2
- SNXLYHMIPDRNOR-UHFFFAOYSA-N N-[2-(2-amino-5-methoxyanilino)ethyl]propanamide Chemical compound C(CC)(=O)NCCNC1=C(C=CC(=C1)OC)N SNXLYHMIPDRNOR-UHFFFAOYSA-N 0.000 description 2
- SZHXAORWWBLFJL-UHFFFAOYSA-N N-[2-(5-methoxy-2-nitroanilino)ethyl]butanamide Chemical compound C(CCC)(=O)NCCNC1=C(C=CC(=C1)OC)[N+](=O)[O-] SZHXAORWWBLFJL-UHFFFAOYSA-N 0.000 description 2
- QWUMETXCKRUZGB-UHFFFAOYSA-N N-[2-(5-methoxy-2-nitroanilino)ethyl]cyclobutanecarboxamide Chemical compound C1(CCC1)C(=O)NCCNC1=C(C=CC(=C1)OC)[N+](=O)[O-] QWUMETXCKRUZGB-UHFFFAOYSA-N 0.000 description 2
- KOJJXPWIAPARBO-UHFFFAOYSA-N N-[2-(5-methoxy-2-nitroanilino)ethyl]cyclohexanecarboxamide Chemical compound C1(CCCCC1)C(=O)NCCNC1=C(C=CC(=C1)OC)[N+](=O)[O-] KOJJXPWIAPARBO-UHFFFAOYSA-N 0.000 description 2
- BIHPHHVVTMEWIK-UHFFFAOYSA-N N-[2-(5-methoxy-2-nitroanilino)ethyl]cyclopentanecarboxamide Chemical compound C1(CCCC1)C(=O)NCCNC1=C(C=CC(=C1)OC)[N+](=O)[O-] BIHPHHVVTMEWIK-UHFFFAOYSA-N 0.000 description 2
- FIPXSXNCNODHHT-UHFFFAOYSA-N N-[2-(5-methoxy-2-nitroanilino)ethyl]cyclopropanecarboxamide Chemical compound C1(CC1)C(=O)NCCNC1=C(C=CC(=C1)OC)[N+](=O)[O-] FIPXSXNCNODHHT-UHFFFAOYSA-N 0.000 description 2
- IPPCQMOCZIQTFY-UHFFFAOYSA-N N-[3-(2-amino-5-methoxyanilino)propyl]acetamide Chemical compound C(C)(=O)NCCCNC1=C(C=CC(=C1)OC)N IPPCQMOCZIQTFY-UHFFFAOYSA-N 0.000 description 2
- IMFOPKPNCIDKJN-UHFFFAOYSA-N N-[3-(5-methoxy-2-nitroanilino)propyl]acetamide Chemical compound C(C)(=O)NCCCNC1=C(C=CC(=C1)OC)[N+](=O)[O-] IMFOPKPNCIDKJN-UHFFFAOYSA-N 0.000 description 2
- 229920002565 Polyethylene Glycol 400 Polymers 0.000 description 2
- SMWDFEZZVXVKRB-UHFFFAOYSA-N Quinoline Chemical compound N1=CC=CC2=CC=CC=C21 SMWDFEZZVXVKRB-UHFFFAOYSA-N 0.000 description 2
- OKJPEAGHQZHRQV-UHFFFAOYSA-N Triiodomethane Natural products IC(I)I OKJPEAGHQZHRQV-UHFFFAOYSA-N 0.000 description 2
- 125000003277 amino group Chemical group 0.000 description 2
- 230000006399 behavior Effects 0.000 description 2
- YZJGKSLPSGPFEV-UHFFFAOYSA-N benzyl 2-(3-oxo-6-phenylmethoxyxanthen-9-yl)benzoate Chemical compound C=1C=CC=C(C2=C3C=CC(=O)C=C3OC3=CC(OCC=4C=CC=CC=4)=CC=C32)C=1C(=O)OCC1=CC=CC=C1 YZJGKSLPSGPFEV-UHFFFAOYSA-N 0.000 description 2
- 239000008280 blood Substances 0.000 description 2
- 210000004369 blood Anatomy 0.000 description 2
- 150000001649 bromium compounds Chemical group 0.000 description 2
- 125000001246 bromo group Chemical group Br* 0.000 description 2
- 239000000872 buffer Substances 0.000 description 2
- DNSISZSEWVHGLH-UHFFFAOYSA-N butanamide Chemical compound CCCC(N)=O DNSISZSEWVHGLH-UHFFFAOYSA-N 0.000 description 2
- 239000003153 chemical reaction reagent Substances 0.000 description 2
- MYSWGUAQZAJSOK-UHFFFAOYSA-N ciprofloxacin Chemical compound C12=CC(N3CCNCC3)=C(F)C=C2C(=O)C(C(=O)O)=CN1C1CC1 MYSWGUAQZAJSOK-UHFFFAOYSA-N 0.000 description 2
- 238000001816 cooling Methods 0.000 description 2
- MFNYBOWJWGPXFM-UHFFFAOYSA-N cyclobutanecarboxamide Chemical compound NC(=O)C1CCC1 MFNYBOWJWGPXFM-UHFFFAOYSA-N 0.000 description 2
- JBDSSBMEKXHSJF-UHFFFAOYSA-N cyclopentanecarboxylic acid Chemical compound OC(=O)C1CCCC1 JBDSSBMEKXHSJF-UHFFFAOYSA-N 0.000 description 2
- 238000004090 dissolution Methods 0.000 description 2
- 230000008406 drug-drug interaction Effects 0.000 description 2
- 125000006575 electron-withdrawing group Chemical group 0.000 description 2
- 238000010579 first pass effect Methods 0.000 description 2
- 238000003818 flash chromatography Methods 0.000 description 2
- 238000002795 fluorescence method Methods 0.000 description 2
- 229910052731 fluorine Inorganic materials 0.000 description 2
- 239000011737 fluorine Substances 0.000 description 2
- 125000005817 fluorobutyl group Chemical group [H]C([H])(F)C([H])([H])C([H])([H])C([H])([H])* 0.000 description 2
- 150000004820 halides Chemical class 0.000 description 2
- 230000002440 hepatic effect Effects 0.000 description 2
- 238000004128 high performance liquid chromatography Methods 0.000 description 2
- 238000002868 homogeneous time resolved fluorescence Methods 0.000 description 2
- 229940088597 hormone Drugs 0.000 description 2
- 239000005556 hormone Substances 0.000 description 2
- 150000004677 hydrates Chemical class 0.000 description 2
- PQNFLJBBNBOBRQ-UHFFFAOYSA-N indane Chemical compound C1=CC=C2CCCC2=C1 PQNFLJBBNBOBRQ-UHFFFAOYSA-N 0.000 description 2
- 150000002475 indoles Chemical class 0.000 description 2
- 239000003112 inhibitor Substances 0.000 description 2
- 238000002347 injection Methods 0.000 description 2
- 239000007924 injection Substances 0.000 description 2
- INQOMBQAUSQDDS-UHFFFAOYSA-N iodomethane Chemical compound IC INQOMBQAUSQDDS-UHFFFAOYSA-N 0.000 description 2
- 239000007788 liquid Substances 0.000 description 2
- 210000004185 liver Anatomy 0.000 description 2
- 230000007056 liver toxicity Effects 0.000 description 2
- 208000024714 major depressive disease Diseases 0.000 description 2
- 230000001404 mediated effect Effects 0.000 description 2
- 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 description 2
- ISJBNGNVDYVCJK-UHFFFAOYSA-N n-[2-(5-methoxy-2-nitroanilino)ethyl]acetamide Chemical compound COC1=CC=C([N+]([O-])=O)C(NCCNC(C)=O)=C1 ISJBNGNVDYVCJK-UHFFFAOYSA-N 0.000 description 2
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 description 2
- 229940126701 oral medication Drugs 0.000 description 2
- JLFNLZLINWHATN-UHFFFAOYSA-N pentaethylene glycol Chemical compound OCCOCCOCCOCCOCCO JLFNLZLINWHATN-UHFFFAOYSA-N 0.000 description 2
- 239000000546 pharmaceutical excipient Substances 0.000 description 2
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 description 2
- 230000001766 physiological effect Effects 0.000 description 2
- 229910000027 potassium carbonate Inorganic materials 0.000 description 2
- 235000019260 propionic acid Nutrition 0.000 description 2
- AQHHHDLHHXJYJD-UHFFFAOYSA-N propranolol Chemical compound C1=CC=C2C(OCC(O)CNC(C)C)=CC=CC2=C1 AQHHHDLHHXJYJD-UHFFFAOYSA-N 0.000 description 2
- 125000006239 protecting group Chemical group 0.000 description 2
- 238000000159 protein binding assay Methods 0.000 description 2
- 239000011541 reaction mixture Substances 0.000 description 2
- 238000007363 ring formation reaction Methods 0.000 description 2
- 229920006395 saturated elastomer Polymers 0.000 description 2
- 239000012453 solvate Substances 0.000 description 2
- 238000012453 sprague-dawley rat model Methods 0.000 description 2
- 238000004885 tandem mass spectrometry Methods 0.000 description 2
- ADLULGUICPPQES-UHFFFAOYSA-N tert-butyl n-[2-[(5-amino-2,3-dihydro-1-benzofuran-4-yl)amino]ethyl]carbamate Chemical compound C1=C(N)C(NCCNC(=O)OC(C)(C)C)=C2CCOC2=C1 ADLULGUICPPQES-UHFFFAOYSA-N 0.000 description 2
- CXWXQJXEFPUFDZ-UHFFFAOYSA-N tetralin Chemical compound C1=CC=C2CCCCC2=C1 CXWXQJXEFPUFDZ-UHFFFAOYSA-N 0.000 description 2
- XFNJVJPLKCPIBV-UHFFFAOYSA-N trimethylenediamine Chemical compound NCCCN XFNJVJPLKCPIBV-UHFFFAOYSA-N 0.000 description 2
- NQPDZGIKBAWPEJ-UHFFFAOYSA-N valeric acid Chemical compound CCCCC(O)=O NQPDZGIKBAWPEJ-UHFFFAOYSA-N 0.000 description 2
- 125000004178 (C1-C4) alkyl group Chemical group 0.000 description 1
- 125000000229 (C1-C4)alkoxy group Chemical group 0.000 description 1
- 125000006592 (C2-C3) alkenyl group Chemical group 0.000 description 1
- CSNIZNHTOVFARY-UHFFFAOYSA-N 1,2-benzothiazole Chemical class C1=CC=C2C=NSC2=C1 CSNIZNHTOVFARY-UHFFFAOYSA-N 0.000 description 1
- KTZQTRPPVKQPFO-UHFFFAOYSA-N 1,2-benzoxazole Chemical class C1=CC=C2C=NOC2=C1 KTZQTRPPVKQPFO-UHFFFAOYSA-N 0.000 description 1
- BCMCBBGGLRIHSE-UHFFFAOYSA-N 1,3-benzoxazole Chemical compound C1=CC=C2OC=NC2=C1 BCMCBBGGLRIHSE-UHFFFAOYSA-N 0.000 description 1
- ALAXBXFNLZRUAF-UHFFFAOYSA-N 1-(5-methoxy-2-nitrophenyl)ethane-1,2-diamine Chemical compound COC=1C=CC(=C(C=1)C(CN)N)[N+](=O)[O-] ALAXBXFNLZRUAF-UHFFFAOYSA-N 0.000 description 1
- LGQJGYKBPMYOQM-UHFFFAOYSA-N 1-(5-methoxy-2-nitrophenyl)propane-1,2-diamine Chemical compound COC=1C=CC(=C(C=1)C(C(C)N)N)[N+](=O)[O-] LGQJGYKBPMYOQM-UHFFFAOYSA-N 0.000 description 1
- ISUYUHZHVWFBQT-UHFFFAOYSA-N 1-n-(5-methoxy-2-nitrophenyl)propane-1,2-diamine Chemical compound COC1=CC=C([N+]([O-])=O)C(NCC(C)N)=C1 ISUYUHZHVWFBQT-UHFFFAOYSA-N 0.000 description 1
- LSTRKXWIZZZYAS-UHFFFAOYSA-N 2-bromoacetyl bromide Chemical compound BrCC(Br)=O LSTRKXWIZZZYAS-UHFFFAOYSA-N 0.000 description 1
- YAFGHMIAFYQSCF-UHFFFAOYSA-N 7-ethoxy-2-oxochromene-3-carbonitrile Chemical compound C1=C(C#N)C(=O)OC2=CC(OCC)=CC=C21 YAFGHMIAFYQSCF-UHFFFAOYSA-N 0.000 description 1
- HAZHUELNIGDYQH-UHFFFAOYSA-N 7-methoxy-4-(trifluoromethyl)chromen-2-one Chemical compound FC(F)(F)C1=CC(=O)OC2=CC(OC)=CC=C21 HAZHUELNIGDYQH-UHFFFAOYSA-N 0.000 description 1
- LJNCNXXYHHZALN-UHFFFAOYSA-N 7-phenylmethoxy-3-(trifluoromethyl)chromen-2-one Chemical compound C1=C2OC(=O)C(C(F)(F)F)=CC2=CC=C1OCC1=CC=CC=C1 LJNCNXXYHHZALN-UHFFFAOYSA-N 0.000 description 1
- 208000024827 Alzheimer disease Diseases 0.000 description 1
- 241000894006 Bacteria Species 0.000 description 1
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 1
- 206010006187 Breast cancer Diseases 0.000 description 1
- 208000026310 Breast neoplasm Diseases 0.000 description 1
- CPELXLSAUQHCOX-UHFFFAOYSA-M Bromide Chemical compound [Br-] CPELXLSAUQHCOX-UHFFFAOYSA-M 0.000 description 1
- 239000004215 Carbon black (E152) Substances 0.000 description 1
- VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 description 1
- 208000019888 Circadian rhythm sleep disease Diseases 0.000 description 1
- 241000195493 Cryptophyta Species 0.000 description 1
- 208000005038 Cytochrome P-450 CYP1A2 Inducers Diseases 0.000 description 1
- 102100036194 Cytochrome P450 2A6 Human genes 0.000 description 1
- 241000196324 Embryophyta Species 0.000 description 1
- 241000233866 Fungi Species 0.000 description 1
- 108091006027 G proteins Proteins 0.000 description 1
- 102000030782 GTP binding Human genes 0.000 description 1
- 108091000058 GTP-Binding Proteins 0.000 description 1
- 238000010268 HPLC based assay Methods 0.000 description 1
- 206010019851 Hepatotoxicity Diseases 0.000 description 1
- 101000875170 Homo sapiens Cytochrome P450 2A6 Proteins 0.000 description 1
- 208000001456 Jet Lag Syndrome Diseases 0.000 description 1
- PSDIUJLUHADTPZ-UHFFFAOYSA-N N-[1-(5-methoxy-2-nitroanilino)propan-2-yl]acetamide Chemical compound C(C)(=O)NC(CNC1=C(C=CC(=C1)OC)[N+](=O)[O-])C PSDIUJLUHADTPZ-UHFFFAOYSA-N 0.000 description 1
- MZYZUHREBFATJZ-UHFFFAOYSA-N N-[2-(2-amino-5-methoxyanilino)ethyl]-2-bromoacetamide Chemical compound NC1=C(C=C(C=C1)OC)NCCNC(CBr)=O MZYZUHREBFATJZ-UHFFFAOYSA-N 0.000 description 1
- LZJNIRIDUQVILC-UHFFFAOYSA-N N-[2-(2-amino-5-methoxyanilino)ethyl]cyclobutanecarboxamide Chemical compound C1(CCC1)C(=O)NCCNC1=C(C=CC(=C1)OC)N LZJNIRIDUQVILC-UHFFFAOYSA-N 0.000 description 1
- GYVLLMRGFQEQJZ-UHFFFAOYSA-N N-[2-(5-methoxy-2-nitroanilino)ethyl]propanamide Chemical compound C(CC)(=O)NCCNC1=C(C=CC(=C1)OC)[N+](=O)[O-] GYVLLMRGFQEQJZ-UHFFFAOYSA-N 0.000 description 1
- ACFIXJIJDZMPPO-NNYOXOHSSA-N NADPH Chemical compound C1=CCC(C(=O)N)=CN1[C@H]1[C@H](O)[C@H](O)[C@@H](COP(O)(=O)OP(O)(=O)OC[C@@H]2[C@H]([C@@H](OP(O)(O)=O)[C@@H](O2)N2C3=NC=NC(N)=C3N=C2)O)O1 ACFIXJIJDZMPPO-NNYOXOHSSA-N 0.000 description 1
- 208000012902 Nervous system disease Diseases 0.000 description 1
- 208000025966 Neurological disease Diseases 0.000 description 1
- 241000282372 Panthera onca Species 0.000 description 1
- 208000018737 Parkinson disease Diseases 0.000 description 1
- ATJFFYVFTNAWJD-UHFFFAOYSA-N Tin Chemical compound [Sn] ATJFFYVFTNAWJD-UHFFFAOYSA-N 0.000 description 1
- 241000251539 Vertebrata <Metazoa> Species 0.000 description 1
- 241000947853 Vibrionales Species 0.000 description 1
- 238000002835 absorbance Methods 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 230000002378 acidificating effect Effects 0.000 description 1
- 150000007513 acids Chemical class 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 208000009956 adenocarcinoma Diseases 0.000 description 1
- 239000000443 aerosol Substances 0.000 description 1
- 238000013019 agitation Methods 0.000 description 1
- 230000003113 alkalizing effect Effects 0.000 description 1
- 125000004183 alkoxy alkyl group Chemical group 0.000 description 1
- 125000003282 alkyl amino group Chemical group 0.000 description 1
- 125000005119 alkyl cycloalkyl group Chemical group 0.000 description 1
- 150000001350 alkyl halides Chemical class 0.000 description 1
- HSFWRNGVRCDJHI-UHFFFAOYSA-N alpha-acetylene Natural products C#C HSFWRNGVRCDJHI-UHFFFAOYSA-N 0.000 description 1
- 150000001408 amides Chemical group 0.000 description 1
- MDFFNEOEWAXZRQ-UHFFFAOYSA-N aminyl Chemical compound [NH2] MDFFNEOEWAXZRQ-UHFFFAOYSA-N 0.000 description 1
- 150000008064 anhydrides Chemical class 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- 239000005557 antagonist Substances 0.000 description 1
- 230000001093 anti-cancer Effects 0.000 description 1
- 230000003556 anti-epileptic effect Effects 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 230000003078 antioxidant effect Effects 0.000 description 1
- 229940054051 antipsychotic indole derivative Drugs 0.000 description 1
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 1
- RFRXIWQYSOIBDI-UHFFFAOYSA-N benzarone Chemical compound CCC=1OC2=CC=CC=C2C=1C(=O)C1=CC=C(O)C=C1 RFRXIWQYSOIBDI-UHFFFAOYSA-N 0.000 description 1
- 150000001555 benzenes Chemical group 0.000 description 1
- 239000003181 biological factor Substances 0.000 description 1
- 229940098773 bovine serum albumin Drugs 0.000 description 1
- KDPAWGWELVVRCH-UHFFFAOYSA-N bromoacetic acid Chemical compound OC(=O)CBr KDPAWGWELVVRCH-UHFFFAOYSA-N 0.000 description 1
- 229920005557 bromobutyl Polymers 0.000 description 1
- RDHPKYGYEGBMSE-UHFFFAOYSA-N bromoethane Chemical compound CCBr RDHPKYGYEGBMSE-UHFFFAOYSA-N 0.000 description 1
- 125000005998 bromoethyl group Chemical group 0.000 description 1
- 125000005997 bromomethyl group Chemical group 0.000 description 1
- 125000004369 butenyl group Chemical group C(=CCC)* 0.000 description 1
- 125000000484 butyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 125000000480 butynyl group Chemical group [*]C#CC([H])([H])C([H])([H])[H] 0.000 description 1
- DVECBJCOGJRVPX-UHFFFAOYSA-N butyryl chloride Chemical compound CCCC(Cl)=O DVECBJCOGJRVPX-UHFFFAOYSA-N 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 150000001721 carbon Chemical group 0.000 description 1
- 239000003054 catalyst Substances 0.000 description 1
- 239000013553 cell monolayer Substances 0.000 description 1
- 239000006285 cell suspension Substances 0.000 description 1
- 230000001413 cellular effect Effects 0.000 description 1
- 210000003169 central nervous system Anatomy 0.000 description 1
- 208000015114 central nervous system disease Diseases 0.000 description 1
- 125000003636 chemical group Chemical group 0.000 description 1
- 229920005556 chlorobutyl Polymers 0.000 description 1
- 125000002603 chloroethyl group Chemical group [H]C([*])([H])C([H])([H])Cl 0.000 description 1
- 125000004218 chloromethyl group Chemical group [H]C([H])(Cl)* 0.000 description 1
- 230000001068 chronobiotic effect Effects 0.000 description 1
- 229960003405 ciprofloxacin Drugs 0.000 description 1
- 230000002060 circadian Effects 0.000 description 1
- 230000027288 circadian rhythm Effects 0.000 description 1
- 210000001072 colon Anatomy 0.000 description 1
- 239000006071 cream Substances 0.000 description 1
- LDHQCZJRKDOVOX-NSCUHMNNSA-N crotonic acid Chemical compound C\C=C\C(O)=O LDHQCZJRKDOVOX-NSCUHMNNSA-N 0.000 description 1
- 239000012043 crude product Substances 0.000 description 1
- 238000002425 crystallisation Methods 0.000 description 1
- 230000008025 crystallization Effects 0.000 description 1
- JFWMYCVMQSLLOO-UHFFFAOYSA-N cyclobutanecarbonyl chloride Chemical compound ClC(=O)C1CCC1 JFWMYCVMQSLLOO-UHFFFAOYSA-N 0.000 description 1
- TXWOGHSRPAYOML-UHFFFAOYSA-N cyclobutanecarboxylic acid Chemical compound OC(=O)C1CCC1 TXWOGHSRPAYOML-UHFFFAOYSA-N 0.000 description 1
- 125000001995 cyclobutyl group Chemical group [H]C1([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 1
- RVOJTCZRIKWHDX-UHFFFAOYSA-N cyclohexanecarbonyl chloride Chemical compound ClC(=O)C1CCCCC1 RVOJTCZRIKWHDX-UHFFFAOYSA-N 0.000 description 1
- RHJVIGLEIFVHIJ-UHFFFAOYSA-N cyclohexanecarboxamide Chemical compound NC(=O)C1[CH]CCCC1 RHJVIGLEIFVHIJ-UHFFFAOYSA-N 0.000 description 1
- 125000000113 cyclohexyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 description 1
- WEPUZBYKXNKSDH-UHFFFAOYSA-N cyclopentanecarbonyl chloride Chemical compound ClC(=O)C1CCCC1 WEPUZBYKXNKSDH-UHFFFAOYSA-N 0.000 description 1
- OJEYDZBIAYMFFD-UHFFFAOYSA-N cyclopentanecarboxamide Chemical compound NC(=O)C1C[CH]CC1 OJEYDZBIAYMFFD-UHFFFAOYSA-N 0.000 description 1
- 125000001511 cyclopentyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 1
- ZOOSILUVXHVRJE-UHFFFAOYSA-N cyclopropanecarbonyl chloride Chemical compound ClC(=O)C1CC1 ZOOSILUVXHVRJE-UHFFFAOYSA-N 0.000 description 1
- YMGUBTXCNDTFJI-UHFFFAOYSA-N cyclopropanecarboxylic acid Chemical compound OC(=O)C1CC1 YMGUBTXCNDTFJI-UHFFFAOYSA-N 0.000 description 1
- 125000001559 cyclopropyl group Chemical group [H]C1([H])C([H])([H])C1([H])* 0.000 description 1
- 230000007812 deficiency Effects 0.000 description 1
- 230000001687 destabilization Effects 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- 238000010494 dissociation reaction Methods 0.000 description 1
- 230000005593 dissociations Effects 0.000 description 1
- 231100000673 dose–response relationship Toxicity 0.000 description 1
- 238000001035 drying Methods 0.000 description 1
- 239000000839 emulsion Substances 0.000 description 1
- FPIQZBQZKBKLEI-UHFFFAOYSA-N ethyl 1-[[2-chloroethyl(nitroso)carbamoyl]amino]cyclohexane-1-carboxylate Chemical compound ClCCN(N=O)C(=O)NC1(C(=O)OCC)CCCCC1 FPIQZBQZKBKLEI-UHFFFAOYSA-N 0.000 description 1
- 125000002534 ethynyl group Chemical group [H]C#C* 0.000 description 1
- 230000005284 excitation Effects 0.000 description 1
- 230000001747 exhibiting effect Effects 0.000 description 1
- 230000003631 expected effect Effects 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- GNBHRKFJIUUOQI-UHFFFAOYSA-N fluorescein Chemical class O1C(=O)C2=CC=CC=C2C21C1=CC=C(O)C=C1OC1=CC(O)=CC=C21 GNBHRKFJIUUOQI-UHFFFAOYSA-N 0.000 description 1
- 125000001153 fluoro group Chemical group F* 0.000 description 1
- 125000003784 fluoroethyl group Chemical group [H]C([H])(F)C([H])([H])* 0.000 description 1
- CJOFXWAVKWHTFT-XSFVSMFZSA-N fluvoxamine Chemical compound COCCCC\C(=N/OCCN)C1=CC=C(C(F)(F)F)C=C1 CJOFXWAVKWHTFT-XSFVSMFZSA-N 0.000 description 1
- 229960004038 fluvoxamine Drugs 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 238000002825 functional assay Methods 0.000 description 1
- 125000000524 functional group Chemical group 0.000 description 1
- 239000007902 hard capsule Substances 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 230000010224 hepatic metabolism Effects 0.000 description 1
- 230000007686 hepatotoxicity Effects 0.000 description 1
- 125000006038 hexenyl group Chemical group 0.000 description 1
- 125000004051 hexyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 125000005980 hexynyl group Chemical group 0.000 description 1
- 210000005260 human cell Anatomy 0.000 description 1
- XMBWDFGMSWQBCA-UHFFFAOYSA-N hydrogen iodide Chemical compound I XMBWDFGMSWQBCA-UHFFFAOYSA-N 0.000 description 1
- 230000000147 hypnotic effect Effects 0.000 description 1
- 230000002519 immonomodulatory effect Effects 0.000 description 1
- 238000001566 impedance spectroscopy Methods 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 150000002473 indoazoles Chemical class 0.000 description 1
- 125000001041 indolyl group Chemical group 0.000 description 1
- 239000000411 inducer Substances 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 210000004692 intercellular junction Anatomy 0.000 description 1
- 210000002490 intestinal epithelial cell Anatomy 0.000 description 1
- 230000004068 intracellular signaling Effects 0.000 description 1
- 229940125425 inverse agonist Drugs 0.000 description 1
- 229910052742 iron Inorganic materials 0.000 description 1
- 208000033915 jet lag type circadian rhythm sleep disease Diseases 0.000 description 1
- 238000002372 labelling Methods 0.000 description 1
- 238000013332 literature search Methods 0.000 description 1
- 235000019988 mead Nutrition 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 230000003340 mental effect Effects 0.000 description 1
- 229910052751 metal Inorganic materials 0.000 description 1
- 239000002184 metal Substances 0.000 description 1
- 210000000110 microvilli Anatomy 0.000 description 1
- 230000003278 mimic effect Effects 0.000 description 1
- 230000036651 mood Effects 0.000 description 1
- DUWWHGPELOTTOE-UHFFFAOYSA-N n-(5-chloro-2,4-dimethoxyphenyl)-3-oxobutanamide Chemical compound COC1=CC(OC)=C(NC(=O)CC(C)=O)C=C1Cl DUWWHGPELOTTOE-UHFFFAOYSA-N 0.000 description 1
- VHJSTJIAABRSMS-UHFFFAOYSA-N n-[2-(6-methoxy-2-sulfanylidene-3h-benzimidazol-1-yl)ethyl]acetamide Chemical compound COC1=CC=C2NC(=S)N(CCNC(C)=O)C2=C1 VHJSTJIAABRSMS-UHFFFAOYSA-N 0.000 description 1
- 230000004770 neurodegeneration Effects 0.000 description 1
- 208000015122 neurodegenerative disease Diseases 0.000 description 1
- 238000006386 neutralization reaction Methods 0.000 description 1
- 229930027945 nicotinamide-adenine dinucleotide Natural products 0.000 description 1
- QJGQUHMNIGDVPM-UHFFFAOYSA-N nitrogen group Chemical group [N] QJGQUHMNIGDVPM-UHFFFAOYSA-N 0.000 description 1
- 238000003305 oral gavage Methods 0.000 description 1
- 239000012044 organic layer Substances 0.000 description 1
- 239000003960 organic solvent Substances 0.000 description 1
- 230000008520 organization Effects 0.000 description 1
- 239000002245 particle Substances 0.000 description 1
- DUCKXCGALKOSJF-UHFFFAOYSA-N pentanoyl pentanoate Chemical compound CCCCC(=O)OC(=O)CCCC DUCKXCGALKOSJF-UHFFFAOYSA-N 0.000 description 1
- 125000002255 pentenyl group Chemical group C(=CCCC)* 0.000 description 1
- 125000001147 pentyl group Chemical group C(CCCC)* 0.000 description 1
- 125000005981 pentynyl group Chemical group 0.000 description 1
- 230000008823 permeabilization Effects 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 238000001050 pharmacotherapy Methods 0.000 description 1
- 239000012071 phase Substances 0.000 description 1
- 239000008363 phosphate buffer Substances 0.000 description 1
- 239000006187 pill Substances 0.000 description 1
- 210000004560 pineal gland Anatomy 0.000 description 1
- 229920001184 polypeptide Polymers 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 102000004196 processed proteins & peptides Human genes 0.000 description 1
- 108090000765 processed proteins & peptides Proteins 0.000 description 1
- 230000001737 promoting effect Effects 0.000 description 1
- RZWZRACFZGVKFM-UHFFFAOYSA-N propanoyl chloride Chemical compound CCC(Cl)=O RZWZRACFZGVKFM-UHFFFAOYSA-N 0.000 description 1
- 125000004368 propenyl group Chemical group C(=CC)* 0.000 description 1
- 229960003712 propranolol Drugs 0.000 description 1
- AOHJOMMDDJHIJH-UHFFFAOYSA-N propylenediamine Chemical compound CC(N)CN AOHJOMMDDJHIJH-UHFFFAOYSA-N 0.000 description 1
- 125000002568 propynyl group Chemical group [*]C#CC([H])([H])[H] 0.000 description 1
- IUVKMZGDUIUOCP-BTNSXGMBSA-N quinbolone Chemical compound O([C@H]1CC[C@H]2[C@H]3[C@@H]([C@]4(C=CC(=O)C=C4CC3)C)CC[C@@]21C)C1=CCCC1 IUVKMZGDUIUOCP-BTNSXGMBSA-N 0.000 description 1
- 230000002285 radioactive effect Effects 0.000 description 1
- 239000002287 radioligand Substances 0.000 description 1
- 239000000018 receptor agonist Substances 0.000 description 1
- 229940044601 receptor agonist Drugs 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 230000001850 reproductive effect Effects 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 230000033764 rhythmic process Effects 0.000 description 1
- JQXXHWHPUNPDRT-WLSIYKJHSA-N rifampicin Chemical compound O([C@](C1=O)(C)O/C=C/[C@@H]([C@H]([C@@H](OC(C)=O)[C@H](C)[C@H](O)[C@H](C)[C@@H](O)[C@@H](C)\C=C\C=C(C)/C(=O)NC=2C(O)=C3C([O-])=C4C)C)OC)C4=C1C3=C(O)C=2\C=N\N1CC[NH+](C)CC1 JQXXHWHPUNPDRT-WLSIYKJHSA-N 0.000 description 1
- 229960001225 rifampicin Drugs 0.000 description 1
- 238000002390 rotary evaporation Methods 0.000 description 1
- 208000012672 seasonal affective disease Diseases 0.000 description 1
- 230000028327 secretion Effects 0.000 description 1
- 239000002356 single layer Substances 0.000 description 1
- 239000007901 soft capsule Substances 0.000 description 1
- 239000007858 starting material Substances 0.000 description 1
- 230000000638 stimulation Effects 0.000 description 1
- 238000005556 structure-activity relationship Methods 0.000 description 1
- 239000000829 suppository Substances 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 239000003826 tablet Substances 0.000 description 1
- 230000008685 targeting Effects 0.000 description 1
- 125000005931 tert-butyloxycarbonyl group Chemical group [H]C([H])([H])C(OC(*)=O)(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
- 238000011287 therapeutic dose Methods 0.000 description 1
- 229910052718 tin Inorganic materials 0.000 description 1
- 239000011135 tin Substances 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- LDHQCZJRKDOVOX-UHFFFAOYSA-N trans-crotonic acid Natural products CC=CC(O)=O LDHQCZJRKDOVOX-UHFFFAOYSA-N 0.000 description 1
- 230000009466 transformation Effects 0.000 description 1
- 125000003866 trichloromethyl group Chemical group ClC(Cl)(Cl)* 0.000 description 1
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 description 1
- 238000002371 ultraviolet--visible spectrum Methods 0.000 description 1
- 229940005605 valeric acid Drugs 0.000 description 1
- 210000003462 vein Anatomy 0.000 description 1
- 125000000391 vinyl group Chemical group [H]C([*])=C([H])[H] 0.000 description 1
- 229940088594 vitamin Drugs 0.000 description 1
- 239000011782 vitamin Substances 0.000 description 1
- 229930003231 vitamin Natural products 0.000 description 1
- 235000013343 vitamin Nutrition 0.000 description 1
- 150000003722 vitamin derivatives Chemical class 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D235/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings
- C07D235/02—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings condensed with carbocyclic rings or ring systems
- C07D235/04—Benzimidazoles; Hydrogenated benzimidazoles
- C07D235/24—Benzimidazoles; Hydrogenated benzimidazoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached in position 2
- C07D235/26—Oxygen atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
- A61K31/4184—1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D235/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings
- C07D235/02—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings condensed with carbocyclic rings or ring systems
- C07D235/04—Benzimidazoles; Hydrogenated benzimidazoles
- C07D235/24—Benzimidazoles; Hydrogenated benzimidazoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached in position 2
- C07D235/28—Sulfur atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
- C07D491/04—Ortho-condensed systems
- C07D491/044—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
- C07D491/048—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring the oxygen-containing ring being five-membered
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Neurosurgery (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Pain & Pain Management (AREA)
- Psychiatry (AREA)
- Anesthesiology (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Plural Heterocyclic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| BRBR1020160248140 | 2016-10-24 | ||
| BR102016024814A BR102016024814A2 (pt) | 2016-10-24 | 2016-10-24 | composto, processo de obtenção do composto, composição farmacêutica, uso do composto e método de tratamento de desordens psiquiátricas e/ou distúrbios do sono |
| PCT/BR2017/050320 WO2018076090A1 (en) | 2016-10-24 | 2017-10-23 | Compounds, process for obtaining the compounds, pharmaceutical composition, use of the compounds and method for treating psychiatric disorders and/or sleep disorders |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| KR20190066023A KR20190066023A (ko) | 2019-06-12 |
| KR102594251B1 true KR102594251B1 (ko) | 2023-10-25 |
Family
ID=62023150
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| KR1020197011842A Active KR102594251B1 (ko) | 2016-10-24 | 2017-10-23 | 화합물, 상기 화합물을 얻기 위한 공정, 약제학적 조성물, 상기 화합물의 용도 및 정신 장애 및/또한 수면 장애를 치료하기 위한 방법 |
Country Status (20)
| Country | Link |
|---|---|
| US (2) | US10781182B2 (enExample) |
| EP (2) | EP3529234B1 (enExample) |
| JP (1) | JP7194683B2 (enExample) |
| KR (1) | KR102594251B1 (enExample) |
| CN (2) | CN115181108A (enExample) |
| AR (1) | AR109467A1 (enExample) |
| AU (1) | AU2017351756B2 (enExample) |
| BR (1) | BR102016024814A2 (enExample) |
| CL (1) | CL2019001105A1 (enExample) |
| CO (1) | CO2019004756A2 (enExample) |
| DK (1) | DK3529234T3 (enExample) |
| EC (1) | ECSP19032963A (enExample) |
| ES (2) | ES2970546T3 (enExample) |
| FI (1) | FI3529234T3 (enExample) |
| MX (1) | MX392990B (enExample) |
| PE (2) | PE20250558A1 (enExample) |
| PT (1) | PT3529234T (enExample) |
| SG (2) | SG11201903113TA (enExample) |
| UY (2) | UY40644A (enExample) |
| WO (1) | WO2018076090A1 (enExample) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| LT3640251T (lt) | 2016-10-24 | 2022-03-10 | Astrazeneca Ab | 6,7,8,9-tetrahidro-3h-pirazolo[4,3-f]izochinolino dariniai, tinkami vėžio gydymui |
| BR102016024814A2 (pt) * | 2016-10-24 | 2018-05-08 | Aché Laboratórios Farmacêuticos S.A. | composto, processo de obtenção do composto, composição farmacêutica, uso do composto e método de tratamento de desordens psiquiátricas e/ou distúrbios do sono |
| MX2019008438A (es) | 2017-01-30 | 2019-10-30 | Astrazeneca Ab | Moduladores del receptor de estrogeno. |
| AR121842A1 (es) * | 2020-04-15 | 2022-07-13 | Ache Laboratorios Farmaceuticos Sa | Compuesto de benzimidazol para el tratamiento de trastornos metabólicos |
| IL297216A (en) | 2020-04-24 | 2022-12-01 | Astrazeneca Ab | Dosage regimen for the treatment of cancer |
| JP7719796B2 (ja) | 2020-04-24 | 2025-08-06 | アストラゼネカ・アクチエボラーグ | 医薬製剤 |
Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20070191447A1 (en) | 2004-02-23 | 2007-08-16 | Toru Kodo | Novel heterocyclic compound |
Family Cites Families (19)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FR2658818B1 (fr) | 1990-02-27 | 1993-12-31 | Adir Cie | Nouveaux derives a structure naphtalenique, leur procede de preparation et les compositions pharmaceutiques qui les contiennent. |
| US5260051A (en) | 1990-12-17 | 1993-11-09 | Lever Brothers Company, Division Of Conopco, Inc. | Compositions comprising phosphate ester compounds containing a beneficial reagent component |
| FR2674524B1 (fr) | 1991-03-25 | 1993-05-21 | Adir | Nouveaux amides alkyl heterocycliques, leur procede de preparation et les compositions pharmaceutiques qui les contiennent. |
| FR2680366B1 (fr) | 1991-08-13 | 1995-01-20 | Adir | Nouveaux derives d'arylethylamines, leurs procedes de preparation et les compositions pharmaceutiques qui les contiennent. |
| GB9326192D0 (en) | 1993-12-22 | 1994-02-23 | Glaxo Group Ltd | Chemical compounds |
| US6376666B1 (en) * | 1994-06-10 | 2002-04-23 | Nauchno-Issledovatelsky Institut Farmakologii Rossiiskoi Akademii Meditsinskikh Nauk | 2-mercaptobenzimidazole derivatives possessing pharmacological activity |
| US5496826A (en) | 1994-09-02 | 1996-03-05 | Bristol-Myers Squibb Company | Pharmaceutical methods of using heterocyclic derivatives of N-phenylamides |
| FR2738818B1 (fr) | 1995-09-18 | 1997-12-05 | Valentonine | Nouveaux derives d'oxydation d'indolylalkylamines, et leur utilisation a titre de medicament |
| US6034239A (en) | 1996-03-08 | 2000-03-07 | Takeda Chemical Industries, Ltd. | Tricyclic compounds, their production and use |
| JP2884153B2 (ja) * | 1996-03-08 | 1999-04-19 | 武田薬品工業株式会社 | 三環性化合物、その製造法および剤 |
| ZA9711051B (en) | 1996-12-10 | 1999-06-09 | Bristol Myers Squibb Co | Benzodioxole benzofuran dihydrobenzofuran and benzodioxane melatonergic agents |
| CA2334299A1 (en) | 1998-06-05 | 1999-12-09 | Pierre Dextraze | Heterocyclic cis cyclopropane derivatives as melatonergic agents |
| EP1189900B1 (en) | 1999-06-30 | 2004-01-14 | Bristol-Myers Squibb Company | Heterocyclic aminopyrrolidine derivatives as melatonergic agents |
| EP1467986A1 (en) * | 2002-01-17 | 2004-10-20 | Eli Lilly And Company | Aza-cyclic compounds as modulators of acetylcholine receptors |
| ES2264641B1 (es) * | 2005-06-17 | 2008-03-01 | Quimica Sintetica, S.A. | Procedimiento para la obtencion de derivados de bencimidazol y sus intermedios. |
| WO2008032164A2 (en) * | 2006-09-12 | 2008-03-20 | Pfizer Products Inc. | Benzimidazolone derivatives |
| WO2008051533A2 (en) * | 2006-10-25 | 2008-05-02 | Takeda Pharmaceutical Company Limited | Benzimidazole compounds |
| RU2401831C2 (ru) * | 2008-12-15 | 2010-10-20 | Алла Хем, Ллс | Средство, снижающее влечение к алкоголю, фармацевтическая композиция и способы ее получения, лекарственное средство и способ лечения |
| BR102016024814A2 (pt) * | 2016-10-24 | 2018-05-08 | Aché Laboratórios Farmacêuticos S.A. | composto, processo de obtenção do composto, composição farmacêutica, uso do composto e método de tratamento de desordens psiquiátricas e/ou distúrbios do sono |
-
2016
- 2016-10-24 BR BR102016024814A patent/BR102016024814A2/pt not_active Application Discontinuation
-
2017
- 2017-07-19 UY UY0001040644A patent/UY40644A/es not_active Application Discontinuation
- 2017-07-19 UY UY0001037334A patent/UY37334A/es active IP Right Grant
- 2017-08-30 AR ARP170102402A patent/AR109467A1/es active IP Right Grant
- 2017-10-23 AU AU2017351756A patent/AU2017351756B2/en active Active
- 2017-10-23 CN CN202210815568.3A patent/CN115181108A/zh active Pending
- 2017-10-23 FI FIEP17865155.0T patent/FI3529234T3/fi active
- 2017-10-23 DK DK17865155.0T patent/DK3529234T3/da active
- 2017-10-23 PT PT178651550T patent/PT3529234T/pt unknown
- 2017-10-23 EP EP17865155.0A patent/EP3529234B1/en active Active
- 2017-10-23 US US16/344,721 patent/US10781182B2/en active Active
- 2017-10-23 KR KR1020197011842A patent/KR102594251B1/ko active Active
- 2017-10-23 MX MX2019004782A patent/MX392990B/es unknown
- 2017-10-23 PE PE2023002494A patent/PE20250558A1/es unknown
- 2017-10-23 ES ES17865155T patent/ES2970546T3/es active Active
- 2017-10-23 EP EP20185268.8A patent/EP3741760B1/en active Active
- 2017-10-23 JP JP2019542758A patent/JP7194683B2/ja active Active
- 2017-10-23 SG SG11201903113TA patent/SG11201903113TA/en unknown
- 2017-10-23 SG SG10202009001TA patent/SG10202009001TA/en unknown
- 2017-10-23 ES ES20185268T patent/ES3013994T3/es active Active
- 2017-10-23 WO PCT/BR2017/050320 patent/WO2018076090A1/en not_active Ceased
- 2017-10-23 PE PE2019000861A patent/PE20191046A1/es unknown
- 2017-10-23 CN CN201780079647.XA patent/CN110088092B/zh active Active
-
2019
- 2019-04-23 CL CL2019001105A patent/CL2019001105A1/es unknown
- 2019-05-09 EC ECSENADI201932963A patent/ECSP19032963A/es unknown
- 2019-05-09 CO CONC2019/0004756A patent/CO2019004756A2/es unknown
-
2020
- 2020-05-13 US US15/930,990 patent/US11091445B2/en active Active
Patent Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20070191447A1 (en) | 2004-02-23 | 2007-08-16 | Toru Kodo | Novel heterocyclic compound |
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| KR102594251B1 (ko) | 화합물, 상기 화합물을 얻기 위한 공정, 약제학적 조성물, 상기 화합물의 용도 및 정신 장애 및/또한 수면 장애를 치료하기 위한 방법 | |
| EP4114391B1 (en) | Compositions for use in a method of treating an estrogen receptor associated cancer | |
| EP3196197A1 (en) | Indoleamine-2,3-dioxygenase inhibitor and preparation method therefor | |
| JP6864379B2 (ja) | インドール類似体及びその使用 | |
| EP4378935A1 (en) | Benzo [b] selenophene sting regulating agent, preparation method therefor and application thereof | |
| BG65379B1 (bg) | Индолови производни | |
| JP2025504791A (ja) | ヒドロキシフェニル部分を含む化合物及びその使用 | |
| EP3447045B9 (en) | 1-(1-hydroxy-2,3-dihydro-1h-inden-5-yl)-urea derivatives and related compounds kcnq 2-5 channel activators for treating dysuria | |
| CN113272315A (zh) | 一类类固醇化合物及其用途 | |
| HK40081925A (en) | Compounds, and preparation process, pharmaceutical composition and use thereof | |
| JP2025511343A (ja) | Ｎ－置換キノリノン化合物、その製造方法及びその使用 | |
| CA3042040C (en) | 2-substituted benzimidazolyl compounds, process for obtaining the compounds, pharmaceutical composition, use of the compounds and method for treating psychiatric disorders and/or sleep disorders | |
| HK40011198A (en) | Compounds, process for obtaining the compounds, pharmaceutical composition, use of the compounds and method for treating psychiatric disorders and/or sleep disorders | |
| HK40011198B (en) | Compounds, process for obtaining the compounds, pharmaceutical composition, use of the compounds and method for treating psychiatric disorders and/or sleep disorders | |
| BR112019008197B1 (pt) | Composto, processo de obtenção do composto, composição farmacêutica e uso do composto | |
| WO2014062204A1 (en) | Matrix metalloproteinase inhibitors and methods for the treatment of pain and other diseases | |
| KR102906581B1 (ko) | 올레아난 신남아미드 유도체 및 이의 제조 방법과 용도 | |
| CN115340527B (zh) | 一种bcl-xl抑制剂及其制备方法和用途 | |
| WO2019029613A1 (zh) | 一种氘代喹啉化合物及其制备和用途 | |
| CN101318943A (zh) | 一类取代哌嗪类化合物、其制备方法、用途及包含此类化合物的药物组合物 | |
| Fanini | Synthesis and Chemical Optimization of New Melatonergic Ligands, including Multitarget Compounds | |
| IL322951A (en) | Hydroxyalkyl and methoxyalkyl-modified tryptamines | |
| CN114426541A (zh) | 氮杂芳基化合物及其用途 | |
| HK40081119B (en) | Compositions for use in a method of treating an estrogen receptor associated cancer | |
| HK40081119A (en) | Compositions for use in a method of treating an estrogen receptor associated cancer |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PA0105 | International application |
Patent event date: 20190424 Patent event code: PA01051R01D Comment text: International Patent Application |
|
| PG1501 | Laying open of application | ||
| PA0201 | Request for examination |
Patent event code: PA02012R01D Patent event date: 20201016 Comment text: Request for Examination of Application |
|
| E902 | Notification of reason for refusal | ||
| PE0902 | Notice of grounds for rejection |
Comment text: Notification of reason for refusal Patent event date: 20221031 Patent event code: PE09021S01D |
|
| E701 | Decision to grant or registration of patent right | ||
| PE0701 | Decision of registration |
Patent event code: PE07011S01D Comment text: Decision to Grant Registration Patent event date: 20230925 |
|
| GRNT | Written decision to grant | ||
| PR0701 | Registration of establishment |
Comment text: Registration of Establishment Patent event date: 20231023 Patent event code: PR07011E01D |
|
| PR1002 | Payment of registration fee |
Payment date: 20231023 End annual number: 3 Start annual number: 1 |
|
| PG1601 | Publication of registration |